Delays in Biologic Competition From Biosimilars—The Case of Adilimumab

This Viewpoint uses the case of adalimumab (Humira), the most profitable biologic drug sold in the United States, to discuss factors that limit product competition and the ability of the public to access less expensive but comparably effective biosimilars.

Read the full article here

Related Articles